This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Paclitaxel, combined with human albumin, is a novel chemotherapeutic formulation approved to treat certain cancers, including breast, lung, and pancreatic cancers. This combination uses albumin, a naturally occurring protein, to improve the solubility and delivery of paclitaxel to cancer cells while reducing toxicities associated with conventional solvents. 

The U.S. Food and Drug Administration (FDA) approved this formulation in January 2005, following clinical trials that highlighted its improved safety profile and efficacy. By leveraging albumin-bound nanoparticles, this treatment marked a significant advancement in cancer care, offering a more tolerable and effective option for patients.

Mechanism of Action of undefined

This molecule works by stabilising microtubules—key structures involved in cell division. It prevents these structures from breaking down, effectively halting the process of cell division. Since cancer cells divide more rapidly than normal cells, this mechanism specifically targets and destroys them. The inclusion of albumin enhances the drug’s transport to cancer cells via natural albumin receptor pathways, improving its concentration in tumour tissues while minimising systemic toxicity.

Uses of undefined

Paclitaxel, Human Albumin, is FDA-approved for the treatment of:

  • Metastatic breast cancer.
  • Non-small cell lung cancer (in combination with carboplatin).
  • Metastatic pancreatic cancer (in combination with gemcitabine).

undefined Drug administaration and Dosage available

This medication is administered as an intravenous infusion under medical supervision. The dosage varies depending on the type and severity of the cancer and the patient’s overall condition. Commonly available dosages include:

  • 100 mg/vial
  • 250 mg/vial

Treatment is typically repeated every three weeks, with adjustments made based on the patient’s response and tolerance.

Warnings, Precautions and Side Effects of undefined

Warnings

  • Severe hypersensitivity reactions: Avoid in patients with prior severe allergic reactions to paclitaxel or albumin.
  • Myelosuppression: Can lead to dangerously low white blood cell counts and infections.
  • Peripheral neuropathy: High risk of nerve damage, requiring monitoring for symptoms.
  • Liver impairment: Requires dosage adjustments in patients with hepatic dysfunction.
  • Pregnancy and lactation: Not recommended due to potential harm to the fetus or nursing infant.

Precautions

Patients should inform their healthcare provider about existing medical conditions, especially liver disease, low blood counts, or neuropathy. Regular blood tests are essential to monitor the impact of treatment. It is crucial to avoid grapefruit or grapefruit juice as they may interfere with drug metabolism. Women of childbearing age should use effective contraception during and after treatment to prevent pregnancy-related risks. Maintaining hydration and reporting any unusual symptoms, such as fever or unusual bleeding, are critical during therapy.

Side Effects

Common Side Effects

  • Fatigue and weakness
  • Hair loss (alopecia)
  • Nausea and vomiting
  • Joint and muscle pain
  • Diarrhea

Serious Side Effects

  • Severe neutropenia (low white blood cell count)
  • Peripheral neuropathy (tingling or numbness in extremities)
  • Allergic reactions (rash, difficulty breathing)
  • Pulmonary toxicity
  • Cardiovascular complications such as low blood pressure

Word Of Advice

This medication should be administered only in a clinical setting by trained professionals. Patients should adhere to the treatment schedule and report any persistent or severe side effects, such as unusual bruising or signs of infection. Eating a balanced diet and staying well-hydrated can help manage some side effects. Avoid any over-the-counter medications, herbal supplements, or significant dietary changes without consulting your doctor, as these may interact with the treatment.

Frequently Asked Question

References

  1. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007 Aug;2(4):415-23. doi: 10.2217/17435889.2.4.415. PMID: 17716129. https://pubmed.ncbi.nlm.nih.gov/17716129/
  2. https://pubs.rsc.org/en/content/articlelanding/2014/md/c4md00200h
  3. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/paclitaxel-albumin-stabilized-nanoparticle-formulation

Disclaimer

This content is for informational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare provider for personalised treatment recommendations.